School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Pharmacol Res. 2019 Aug;146:104318. doi: 10.1016/j.phrs.2019.104318. Epub 2019 Jun 20.
Si-Miao-Yong-An decoction (SMYAD), a Chinese herbal formula, has been used in treating ischemic cardiovascular diseases. However, the cardioprotective mechanism of SMYAD treating heart failure (HF) remains unclear. Herein we investigated the effect of SMYAD on isoprenaline (ISO)-induced HF in C57BL/6 mice. Cardiac function and pathological changes in myocardial tissue were evaluated as well as A-type natriuretic peptide (ANP) and brain natriuretic peptide (BNP) expression. The underlying mechanism of SMYAD was deciphered using UHPLC MS/MS coupled with bioinformatics and was verified. SMYAD treatment significantly ameliorated cardiac function, reduced collagen deposition and cardiomyocyte apoptosis, reversed cardiac hypertrophy and down-regulated the expression levels of ANP and BNP mRNA compared with those in HF mice. Decipherment analyses based on 138 ingredients prompted that anti-oxidation was the key mechanism of SMYAD treating HF. In vitro and in vivo, SMYAD showed antioxidant activity, significantly up-regulated superoxide dismutase (SOD)-1 and SOD-2 mRNA expression levels and reduced NADP/NADPH ratio. Moreover, the increased expression levels of NADPH oxidase 2 (NOX2), p47 and Rac family small GTPase 1 (Rac1) were obviously ameliorated after SMYAD treatment. Together, this study reveals that SMYAD can apparently improve heart function of ISO-induced HF mice by inhibiting the myocardial oxidative stress through restoring the equilibrium of SOD and NOX2.
四物汤(SMYAD)是一种中药方剂,用于治疗缺血性心血管疾病。然而,SMYAD 治疗心力衰竭(HF)的心脏保护机制尚不清楚。在此,我们研究了 SMYAD 对 C57BL/6 小鼠异丙肾上腺素(ISO)诱导的 HF 的影响。评估了心脏功能和心肌组织的病理变化以及 A 型利钠肽(ANP)和脑利钠肽(BNP)的表达。使用 UHPLC MS/MS 结合生物信息学方法揭示了 SMYAD 的潜在机制,并进行了验证。与 HF 小鼠相比,SMYAD 治疗可显著改善心脏功能,减少胶原沉积和心肌细胞凋亡,逆转心脏肥大并下调 ANP 和 BNP mRNA 的表达水平。基于 138 种成分的破译分析表明,抗氧化作用是 SMYAD 治疗 HF 的关键机制。在体外和体内,SMYAD 均表现出抗氧化活性,显著上调超氧化物歧化酶(SOD)-1 和 SOD-2 mRNA 表达水平,并降低 NADP/NADPH 比值。此外,SMYAD 治疗后,NADPH 氧化酶 2(NOX2)、p47 和 Rac 家族小 GTP 酶 1(Rac1)的表达水平增加明显得到改善。总之,本研究表明,SMYAD 通过恢复 SOD 和 NOX2 的平衡,明显改善 ISO 诱导的 HF 小鼠的心脏功能,抑制心肌氧化应激。